menu
    • menu
    [{"orgOrder":0,"company":"Curasight","sponsor":"ABX CRO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"64-Cu DOTA-AE105","moa":"uPAR","graph1":"Oncology","graph2":"Phase II","graph3":"Curasight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curasight \/ ABX CRO","highestDevelopmentStatusID":"8","companyTruncated":"Curasight \/ ABX CRO"},{"orgOrder":0,"company":"Curasight","sponsor":"Curasight","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"68-Ga NOTA-AE105","moa":"uPAR","graph1":"Oncology","graph2":"Phase I","graph3":"Curasight","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curasight \/ Curasight","highestDevelopmentStatusID":"6","companyTruncated":"Curasight \/ Curasight"},{"orgOrder":0,"company":"Curasight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga NOTA-AE105","moa":"uPAR","graph1":"Oncology","graph2":"Preclinical","graph3":"Curasight","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curasight \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Curasight \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Curasight

    Menu

    Curasight

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Curasight

                            Denmark arrow
                            AllPack Indonesia
                            Not Confirmed

                            Curasight

                            Denmark arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 64-Cu DOTA-AE105

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : ABX CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer

                            Details : 64-Cu DOTA-AE105 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 26, 2024

                            Lead Product(s) : 64-Cu DOTA-AE105

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : ABX CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Curasight

                            Denmark arrow
                            AllPack Indonesia
                            Not Confirmed

                            Curasight

                            Denmark arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga NOTA-AE105

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)

                            Details : uTREAT® is new type of targeted radiation therapy, targeting and irradiating the cancer cells and almost not healthy tissue. By injecting a substance that seeks all cancer cells, this offers a personalised and tailored therapy to each patient.

                            Product Name : uTREAT

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 07, 2023

                            Lead Product(s) : 68-Ga NOTA-AE105

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Curasight

                            Denmark arrow
                            AllPack Indonesia
                            Not Confirmed

                            Curasight

                            Denmark arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga NOTA-AE105

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Rigshospitalet

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomo...

                            Details : 68-Ga NOTA-AE105 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 07, 2015

                            Lead Product(s) : 68-Ga NOTA-AE105

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Rigshospitalet

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth